Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04803305 · ClinicalTrials.gov registry record · Phase 1
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 20
- Study locations
NCT04803305 is a Phase 1 study of Breast Cancer and Prostate Cancer that has completed, run by Pfizer. The registered enrollment target is 18 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT04803305, a Phase 1 study of Breast Cancer and Prostate Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under the skin) doses.
Conditions Studied
Interventions
- DRUG PF-06946860
- DRUG Placebo for PF-06946860
Study Locations (20)
California
- Tower Hematology Oncology Medical Group (THO) - Beverly Hills
- Ventura County Hematology- Oncology Specialists - Camarillo
- Cedars- Sinai Medical Center - Los Angeles
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Ventura County Hematology Oncology Specialists - Oxnard
- Providence Medical Foundation - Santa Rosa
- Ventura County Hematology-Oncology Specialists - Ventura
Texas
- Mary Crowley Cancer Research - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
- US Oncology Investigational Product Center (IPC) - Irving
- Texas Oncology - Longview Cancer Center - Longview
- Texas Oncology-Paris - Paris
- Texas Oncology- Tyler - Tyler
Montana
- Bozeman Health Cancer Center - Bozeman
- Bozeman Health Deaconess Hospital d/b/a Bozeman Health Clinical Research - Bozeman
- Bozeman Health Deaconess Hospital - Bozeman
Arkansas
- CARTI Cancer Center - Little Rock
Colorado
- Lutheran Medical Center - Wheat Ridge
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-05-11 |
| Est. Completion | 2022-08-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04803305
The ClinicalTrials.gov registry entry for NCT04803305 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which PF-06946860 is the first listed.
NCT04803305 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Texas, Montana.
Frequently Asked Questions
What is clinical trial NCT04803305 about?
NCT04803305 is a clinical study titled "Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia". Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under the skin) doses.
What is the current status of trial NCT04803305?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-05-11. Estimated completion is 2022-08-09.
What conditions does trial NCT04803305 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer.
What interventions are being tested in trial NCT04803305?
The interventions under investigation include: PF-06946860 (DRUG), Placebo for PF-06946860 (DRUG).
Who is sponsoring clinical trial NCT04803305?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04803305 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Indiana, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.